Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-05-31

Clinical Trial Update: Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of CC-96191 in participants with relapsed or refractory acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CC-96191

Snippet

Sponsor: Celgene | Conditions: Leukemia, Myeloid | Phase 1 | Status: TERMINATED